FDA approves Roche’s Vabysmo PFS for three leading causes of vision loss
Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness
Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness
Doxycycline capsules are indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients
This existing GMP compliant facility, located at Bharuch (Unit-1) with ongoing expansion part of the company's strategic capex initiative
The Unit has now received Establishment Inspection Report classifying the facility as Voluntary Action Indicated
This Unit of Shilpa Medicare is engaged in testing biological samples of clinical studies
The facility was inspected from May 7 to May 17, 2024
The company will work closely with the USFDA and is committed to address these comprehensively within stipulated time
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
This clearance is a foundational step in Roche's commitment to enable routine clinical diagnosis with its digital pathology solutions
Subscribe To Our Newsletter & Stay Updated